What does gonadorelin do?

Gonadorelin is a synthetic version of GnRH, also called gonadotropin-releasing hormone. The source describes it as a 10-amino-acid peptide that signals the pituitary to release LH and FSH, with established diagnostic use and historical use for ovulation induction. Off-label TRT-support claims are noted by the source but are not presented as proven by large randomized trials.

How does gonadorelin work?

It acts at GnRH receptors on anterior-pituitary gonadotroph cells. The reported signaling pathway involves phospholipase C, calcium mobilization, and protein kinase C, followed by LH and FSH synthesis and release. Pulsatile exposure is central to the source description: pulse-like delivery can stimulate the axis, while sustained exposure can desensitize receptors and suppress LH and FSH.

Is gonadorelin FDA approved?

The source lists FDA Approved status but also states that the previously approved diagnostic product Factrel has been discontinued and that no FDA-approved gonadorelin product is currently marketed in the US. It further reports availability only as 503A-compounded.

What side effects are reported for gonadorelin?

Reported effects in the source include injection site reactions, headache, flushing, nausea, risk of multiple births, possible worsening of hormone-dependent cancers, and long-term bone density decrease. Individual risk cannot be determined from this draft.

What dose does the source report for gonadorelin?

The source reports a community common dose of 100-500 mcg 2-3x weekly, with a range of 50-500 mcg per dose, and administration by IV, subcutaneous route, or pulsatile pump. It also reports a research/labeling row of 100 mcg IV/SC for diagnostic testing. These entries preserve source-reported values and are not treatment instructions.

Hormonalne Zatwierdzone przez FDA - zatwierdzony w określonych wskazaniach

Gonadorelin

Znany też jako: GnRH, LHRH, Factrel

W skrócie

Zbiór danych PeptiGuide · przegląd sie 2026

Czym jest

Synthetic GnRH peptide where pulsatile timing is central to LH and FSH stimulation.

Status

Zatwierdzone przez FDA

Poziom dowodów: dane kliniczne u ludzi

Typowa dawka

100–500mcg

Badany pod kątem

Hormone stimulation, fertility, TRT support

Postęp badań

PrePrzedkliniczne
IFaza I
IIFaza II
IIIFaza III
IVFaza IV
FDAZatwierdzone przez FDA

Zatwierdzone przez FDA - Zatwierdzone zastosowania z ustalonymi danymi u ludzi

Użyj narzędzi

Prostym językiem

Synthetic GnRH peptide with the sequence pGlu-His-Trp-Ser-Tyr-Gly-Leu-Arg-Pro-Gly-NH2.
Source lists FDA Approved status, with the nuance that the former Factrel diagnostic product is discontinued and no FDA-approved gonadorelin product is currently marketed in the US.
Reported typical community dose is 100-500 mcg 2-3x weekly; administration routes listed are IV, subcutaneous, or pulsatile pump.
Researched or discussed for hormone stimulation, fertility, and TRT support, with TRT-adjunct use described as less strongly trial-backed than established diagnostic biology.

Jak prawdopodobnie działa

Gonadorelin is described as a synthetic GnRH peptide that engages GnRH receptors on gonadotroph cells in the anterior pituitary. The source reports signaling through phospholipase C with calcium and protein kinase C involvement, leading to LH and FSH production and release. Those gonadotropins then influence ovarian or testicular function, including sex-steroid production and gamete development. The source emphasizes pattern of exposure: pulsatile delivery, similar to endogenous GnRH rhythms of about 60 to 120 minutes, supports stimulation, whereas continuous exposure can desensitize and downregulate the receptor and reduce LH and FSH output.

Co pokazują badania

Na jakim etapie są badania

The source frames gonadorelin as an established GnRH molecule rather than an experimental novelty. Diagnostic GnRH stimulation testing is described as established, and pulsatile pump administration is reported in hypogonadotropic hypogonadism, delayed puberty, and fertility induction. Because the peptide is short-lived, the source notes that historical clinical use depended on pumps or frequent administration, while longer-acting GnRH agonists later displaced some uses. The source also describes off-label TRT-adjunct use as common in some clinic and online settings, but supported mainly by mechanism, small-scale experience, or anecdote rather than large randomized comparisons showing superiority over HCG.

Co pokazują

✓ Dane kliniczne u ludzi

Zatwierdzone zastosowania z ustalonymi danymi u ludzi

△ Ograniczenia

Stosowanie wyłącznie zgodnie z zatwierdzoną dokumentacją i pod opieką wykwalifikowanego specjalisty.

Podsumowanie: Previously FDA approved as Factrel for diagnostic use; that brand is discontinued, no FDA-approved gonadorelin product is currently marketed in the US, and the source reports availability only as 503A-compounded. FDA Approved; previously approved Factrel diagnostic product is discontinued, and no FDA-approved gonadorelin product is currently marketed in the US per source.

Typowe dawkowanie

SpołecznośćZbiór danych społeczności

100–500 mcg

2-3x weekly

50 mcgpełny obserwowany zakres500 mcg

Community-reported use is described for TRT support and often alongside HCG protocols. This row is not medical advice and is not presented as validated clinical dosing. · IV, subcutaneous, or pulsatile pump

Dawkowanie badawcze

Zależne od wskazaniaZatwierdzony w określonych wskazaniach - dawki z badań zależą od wskazania

Dawki obserwowane w badaniach

100 mcg IV/SC for diagnostic testing

FDA Approved Labeling - Prescribed dose

Stosowanie wyłącznie zgodnie z zatwierdzoną dokumentacją i pod opieką wykwalifikowanego specjalisty.

Czas trwania: Single dose (diagnostic) or ongoing (therapeutic)
Podanie: IV, subcutaneous, or pulsatile pump

Timing i podanie

Najlepsza pora

Morning or as clinically directed

As prescribed, often pulsatile

Zalecenia żywieniowe

With or without food

Dlaczego taki timing?

The source links gonadorelin use to protocol-specific timing and emphasizes that the delivery pattern changes the biological effect. Pulsatile exposure is associated with LH and FSH stimulation, while continuous exposure can reduce receptor responsiveness and suppress those gonadotropins.

Możliwe skutki uboczne

Nie każdy ich doświadcza. Indywidualne reakcje zależą od dawki, czasu trwania i czynników osobistych.

Injection site reactions
Headache
Flushing
Nausea
Risk of multiple births
May worsen hormone-dependent cancers
Long-term bone density decrease

Nie każdy doświadcza skutków ubocznych, a nasilenie może zależeć od kontekstu, czystości, drogi podania i indywidualnych czynników zdrowotnych.

Źródła

PubMed ClinicalTrials.gov FDA.gov

Najczęstsze pytania

Sekwencja

pGlu-His-Trp-Ser-Tyr-Gly-Leu-Arg-Pro-Gly-NH2

Jeden otwarty zbiór danych

Każdy fakt na tej stronie - dawki, skutki uboczne, referencje - pochodzi z tego samego zbioru danych PeptiGuide, który zasila Tracker, Porównywarkę i Lab.

Przeglądaj zbiór danych

Zapisz na mojej liście Aktualizacje o Gonadorelin

Materiał edukacyjny, nie porada medyczna. Porozmawiaj z lekarzem, zanim podejmiesz działania.

Dyskusja społeczności

Komentarze są moderowane przed publikacją. Trzymajmy się dowodów.

Gonadorelin

Prostym językiemProstym językiem

Jak prawdopodobnie działaJak prawdopodobnie działa

Co pokazują badaniaCo pokazują badania

Typowe dawkowanie

Dawkowanie badawcze

Timing i podanieTiming i podanie

Możliwe skutki uboczneMożliwe skutki uboczne

ŹródłaŹródła

Najczęstsze pytaniaNajczęstsze pytania